Cancer

Cell culture and mouse studies suggest inhibiting HDAC6 could help treat ARID1A-mutant clear cell ovarian cancer. In four ARID1A-mutant clear cell ovarian cancer cell lines, the HDAC6 inhibitor rocilinostat or shRNA targeting HDAC6 increased apoptosis compared with vehicle or non-specific shRNA, respectively. In an orthotopic xenograft mouse model of ARID1A-mutant clear cell ovarian cancer, rocilinostat decreased tumor growth and increased tumor cell apoptosis and survival compared with vehicle. In a genetic mouse model of the indication, rocilinostat decreased tumor growth. Next steps include optimizing and testing undisclosed HDAC6 inhibitors in patient-derived xenograft (PDX) models of ARID1A-mutant clear cell ovarian cancer...